Oppenheimer Asset Management Inc. Arrowhead Pharmaceuticals, Inc. Transaction History

Oppenheimer Asset Management Inc.

$8.04 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 06, 2023	SELL	$28.0 - $40.56 $38,416 - $55,648	-1,372 Reduced 9.83%	12,592 $510,000
Q3 2022 Nov 14, 2022	SELL	$29.63 - $48.31 $14,370 - $23,430	-485 Reduced 3.36%	13,964 $462,000
Q2 2022 Aug 08, 2022	SELL	$27.79 - $50.61 $11,004 - $20,041	-396 Reduced 2.67%	14,449 $509,000
Q1 2022 May 12, 2022	SELL	$39.62 - $69.97 $4,556 - $8,046	-115 Reduced 0.77%	14,845 $683,000
Q4 2021 Feb 02, 2022	SELL	$58.09 - $82.51 $35,028 - $49,753	-603 Reduced 3.87%	14,960 $992,000
Q3 2021 Nov 12, 2021	SELL	$58.38 - $84.96 $40,457 - $58,877	-693 Reduced 4.26%	15,563 $972,000
Q2 2021 Aug 03, 2021	SELL	$62.15 - $90.32 $19,142 - $27,818	-308 Reduced 1.86%	16,256 $1.35 Million
Q1 2021 May 17, 2021	SELL	$61.35 - $90.47 $29,693 - $43,787	-484 Reduced 2.84%	16,564 $1.1 Million
Q4 2020 Feb 11, 2021	SELL	$43.82 - $85.37 $13,759 - $26,806	-314 Reduced 1.81%	17,048 $1.31 Million
Q3 2020 Nov 13, 2020	SELL	$33.21 - $51.27 $3,619 - $5,588	-109 Reduced 0.62%	17,362 $748,000
Q2 2020 Aug 11, 2020	BUY	$26.12 - $43.27 $5,615 - $9,303	215 Added 1.25%	17,471 $755,000
Q1 2020 May 08, 2020	SELL	$20.56 - $63.12 $7,052 - $21,650	-343 Reduced 1.95%	17,256 $496,000
Q4 2019 Feb 07, 2020	SELL	$28.14 - $73.01 $10,749 - $27,889	-382 Reduced 2.12%	17,599 $1.12 Million
Q3 2019 Oct 31, 2019	SELL	$26.26 - $34.86 $8,980 - $11,922	-342 Reduced 1.87%	17,981 $507,000
Q2 2019 Aug 09, 2019	SELL	$17.43 - $28.82 $55,043 - $91,013	-3,158 Reduced 14.7%	18,323 $486,000
Q1 2019 Apr 24, 2019	SELL	$12.05 - $20.18 $64,961 - $108,790	-5,391 Reduced 20.06%	21,481 $395,000
Q4 2018 Jan 30, 2019	BUY	$10.74 - $19.7 $288,605 - $529,378	26,872 New	26,872 $334,000

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.8M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.01B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.

Account